Basudeb Das

When I was in my school and studying science, I was inquisitive to know 'How the human body works'. So, I dove into the world of biology and studied Human Physiology. During my M.Sc., I worked with Ph.D. scholars and professors in my department whose predominant motivation was my raw love for science. I found the research very exciting, had a lot of fun, and realized science is one of the most remarkable ways to serve mankind.

My doctoral studies was mainly focused on the identification of potential therapeutic targets in human soft tissue sarcoma (STS), tumors of mesenchymal origin that are early metastatic, aggressive, and heterogeneous, most of which are resistant to chemotherapy and radiotherapy. Using omics analysis of clinical data together with in-vitro studies, my research identified RRM2 and CYP1A2 as oncogenes and critical regulators associated with STS progression, early metastasis, and chemotherapeutic resistance (Das et al., 2022, Gene; Das et al., 2021, Communications Biology). Further, I found important regulatory PIWI-interacting RNA (piRNA), piR39980 a small non-coding RNAs that targets 3' UTR of RRM2 and CYP1A2. piR-39980-mediated silencing of RRM2 and CYP1A2 inhibits STS proliferation and migration/invasion, inducing cancer cell apoptosis and reverse chemotherapeutic resistance (Das et al., 2019, Mol Carcinogenesis).

In my recent postdoctoral research, I am studying the role of chromatin associated lncRNA in breast cancer development, metastasis and drug resistance. I am focusing on identifying chromatin associated lncRNA and develop ASOs to target this lncRNA to kill breast cancer in PDX/CDX models. Also studying the influence of lncRNA in breast cancer drug resistance development in self-developed breast cancer drug resistance model. I am also doing RNAseq, CHIPseq, IP, MS, RNA-FISH etc. to explore molecular mechanisms behind how this chromatin-associated lncRNA regulates chromatin architecture and gene expression.

https://www.ncbi.nlm.nih.gov/myncbi/basudeb.das.1/bibliography/public/

https://orcid.org/0000-0001-8782-4392

• Travel Awards ($300.00): 2014, LncRNA CLUB organized by UTHealth Houston, MD Anderson Cancer Center and Baylor College of Medicine on 08/23/2024 at Zayed building 11th floor conference/lobby
  2024
• CPRIT Fellowship: 2024, The Cancer Therapeutic Training Program by Gulf Coast Consortia The Cancer Prevention and Research Institute of Texas, USA
• Best Oral Presentation Award: 2019, Recent Advances in Biological Sciences, April 3-4, 2019, Organized by the School of Life Sciences, Sambalpur University, India
• Institute Doctoral Fellowship: 2016, National Institute of Technology Rourkela, India
• Graduate Aptitude Test in Engineering (GATE - Biotechnology) Scholarship: 2016, Department of Higher Education, Ministry of Education, Government of India
• Gold Medal: 2014, M.Sc. in Human Physiology, batch 2012-2014 of Vidyasagar University, India
• Silver Medal: 2012, B.Sc. in Physiology in the Batch 2009-2012 of Vidyasagar University, India

• Nandi SK, Pradhan A, Das B, Das B, Basu S, Mallick B, Dutta A, Sarkar DK, Mukhopadhyay A, Mukhopadhyay S, Bhattacharya R (2022). Kaempferol attenuates viability of ex-vivo cultured post-NACT breast tumor explants through downregulation of p53 induced stemness, inflammation and apoptosis evasion pathways. Pathology – Research and Practice. 237, 154029: 1-11.
• Das B, Sahoo S, Mallick B (2022). HIWI2 induces G2/M cell cycle arrest and apoptosis in human fibrosarcoma via the ROS/DNA damage/p53 axis. Life Sciences. 293, 120353:1-13.
• Das B, Jain N, Mallick B (2022). Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma. GENE. 808,145988:1-14
• Jain N, Das B, Mallick B (2022). miR-197-5p increases Doxorubicin-mediated anticancer cytotoxicity of HT1080 fibrosarcoma cells by decreasing drug efflux. DNA Repair. 109,103259: 1-9
• Das B, Jain N, Mallick B (2021). A piRNA mediates doxorubicin resistance in fibrosarcoma by regulating intracellular drug accumulation and DNA repair via CYP1A2/RRM2. Communications Biology. 4(1):1-18.
• Roy J, Das B, Jain N, Mallick B (2020). Piwi interacting RNA 39980 promotes tumor progression and reduces drug sensitivity in human Neuroblastoma. Journal of Cellular Physiology. 235 (3): 2286-2299.
• Das B, Jain N, Mallick B (2020). piR-39980 promotes cell proliferation, migration, invasion and inhibits apoptosis via repression of SERPINB1 in human osteosarcoma. Biology of the Cell. 112(3):73-91.
• Jain N, Das B, Mallick B (2020). Restoration of microRNA-197 expression suppresses oncogenicity in fibrosarcoma through negative regulation of RAN. IUBMB Life. 72(5):1034-1044.
• Das B, Roy J, Jain N, Mallick B (2019). Tumor suppressive activity of PIWI-interacting RNA in human fibrosarcoma mediated through repression of RRM2. Molecular Carcinogenesis. 58(3):344-357.
• Jain N, Roy J, Das B, Mallick B (2019). miR‐197‐5p inhibits sarcomagenesis and induces cellular senescence via repression of KIAA0101. Molecular Carcinogenesis. 58(8): 1376-1388.
• Yadav KK, Arakha M, Das B, Mallick B, and Jha S (2018). Preferential binding to zinc oxide nanoparticle interface inhibits lysozyme fibrillation and cytotoxicity. International Journal of Biological Macromolecule. 116: 955-965.
• Roy J, Jain N, Singh G, Das B, and Mallick B (2018) Small RNA Proteome as Disease Biomarker: An Incognito Treasure of Clinical Utility. In Mallick B (Eds.) AGO-driven Non-Coding RNAs: Codes to decode the therapeutics of Diseases, Elsevier, United States.

CPRIT Grant RP210043, Cancer Therapeutics Training Program (CTTP) by Gulf Coast Consortia, $91,120.00, 08/01/24, 07/31/25